| SML Genetree Accelerates Global Expansion on Its 10th Anniversary
Building on a decade of accumulated expertise, SML Genetree announced on the 28th that it will accelerate its expansion into global markets, including the U.S., Europe, the Middle East, Asia, and Latin America. Leveraging the experience and technology gained in the domestic market over the past 10 years, the company plans to enter both advanced markets like the U.S. and Europe, as well as emerging markets.
Founded in 2015, SML Genetree has developed molecular diagnostic products across various disease areas, including STD, respiratory infections, tuberculosis, and HPV. Notably, on December 31, 2022, the company surprised the industry by obtaining simultaneous approval for diagnostic kits covering multiple fields such as STDs, cancer, and respiratory infections. In 2023, it recorded approximately $17 million USD in sales, continuing its growth trajectory.
Starting in 2025, SML Genetree plans to actively push into global markets beyond Korea. To this end, it is preparing strategies to enhance its competitiveness, focusing on developing market-specific products and expanding local distribution networks. The company also aims to strengthen product quality and technology to secure a competitive edge, targeting U.S. FDA approval and European CE-IVDR certification for its core products.
In addition, the company is committed to developing tailored products that reflect the disease characteristics and market needs of each region. For example, in the Middle East, SML Genetree plans to develop a self-sampling system for STD testing that aligns with cultural sensitivities, as well as POCT systems for molecular diagnostics. In the U.S., the company intends to provide cancer data analysis services through partnerships with CLIA-certified labs.
Currently, SML Genetree trades with over 30 countries and is strengthening its distribution partnerships with local hubs in key regions such as the Middle East, Asia, and Latin America. These efforts are helping the company increase its global market share.
CEO Dongsoo Lee stated, “Based on the experience and know-how we’ve built in the Korean molecular diagnostics market over the past decade, we will grow into a globally recognized company,” adding, “We will continue to develop customer-friendly products and services that contribute to the advancement of human health.”
New excerpted from https://news.mt.co.kr/mtview.php?no=2025032716103872564
| SML Genetree Accelerates Global Expansion on Its 10th Anniversary
Building on a decade of accumulated expertise, SML Genetree announced on the 28th that it will accelerate its expansion into global markets, including the U.S., Europe, the Middle East, Asia, and Latin America. Leveraging the experience and technology gained in the domestic market over the past 10 years, the company plans to enter both advanced markets like the U.S. and Europe, as well as emerging markets.
Founded in 2015, SML Genetree has developed molecular diagnostic products across various disease areas, including STD, respiratory infections, tuberculosis, and HPV. Notably, on December 31, 2022, the company surprised the industry by obtaining simultaneous approval for diagnostic kits covering multiple fields such as STDs, cancer, and respiratory infections. In 2023, it recorded approximately $17 million USD in sales, continuing its growth trajectory.
Starting in 2025, SML Genetree plans to actively push into global markets beyond Korea. To this end, it is preparing strategies to enhance its competitiveness, focusing on developing market-specific products and expanding local distribution networks. The company also aims to strengthen product quality and technology to secure a competitive edge, targeting U.S. FDA approval and European CE-IVDR certification for its core products.
In addition, the company is committed to developing tailored products that reflect the disease characteristics and market needs of each region. For example, in the Middle East, SML Genetree plans to develop a self-sampling system for STD testing that aligns with cultural sensitivities, as well as POCT systems for molecular diagnostics. In the U.S., the company intends to provide cancer data analysis services through partnerships with CLIA-certified labs.
Currently, SML Genetree trades with over 30 countries and is strengthening its distribution partnerships with local hubs in key regions such as the Middle East, Asia, and Latin America. These efforts are helping the company increase its global market share.
CEO Dongsoo Lee stated, “Based on the experience and know-how we’ve built in the Korean molecular diagnostics market over the past decade, we will grow into a globally recognized company,” adding, “We will continue to develop customer-friendly products and services that contribute to the advancement of human health.”
New excerpted from https://news.mt.co.kr/mtview.php?no=2025032716103872564